The intravesical gemcitabine-releasing system, previously known as TAR-200, treats patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

A healthcare professional places TAR-200 into the bladder using a co-packaged urinary placement catheter. The procedure takes place in an outpatient setting in less than five minutes and requires no general anesthesia or further monitoring. Inlexzo remains in the bladder for three weeks per treatment cycle for up to 14 cycles.

According to J&J, it’s the first and only intravesical drug-releasing system (iDRS) to provide extended local delivery of a cancer medication into the bladder.